Dopamine Agonists and Risk of Lung Cancer in Patients with Restless Legs Syndrome

Overview

Journal Pharmacoepidemiol Drug Saf

Publisher Wiley

Specialties Pharmacology
Public Health

Date 2023 Feb 10

PMID 36760024

Authors

Pilar Hernandez-Con

Justine Shults

Allison W Willis

Yu-Xiao Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the association between long-term use of dopamine agonists (DAs) and the risk of lung cancer in patients with restless legs syndrome (RLS).

Methods: We conducted a retrospective cohort study using Optum Clinformatics® database. We included adults ≥40 years diagnosed with RLS during the study period (1/2006-12/2016). Follow-up started with the first RLS diagnosis and ended on the earliest of: incident diagnosis of lung cancer, end of enrollment in the database or end of the study period. The exposure of interest was cumulative duration of DAs use, measured in a time-varying manner. We constructed a multivariable Cox regression model to estimate HRs and 95% CIs for the association between lung cancer and cumulative durations of DA use, adjusting for potential confounding variables.

Results: We identified 295 042 patients with a diagnosis of RLS. The mean age of the cohort was 62.9; 66.6% were women and 82.3% were white. The prevalence of any DA exposure was 40.3%. Compared to the reference group (no use and ≤1 year), the crude HRs for lung cancer were 1.16 (95% CI 0.99-1.36) and 1.14 (95% CI 0.86-1.51) for 1-3 years and >3 years of cumulative DA use, respectively. The adjusted HR for lung cancer was 1.05 (95% CI 0.88-1.25) for 1-3 years and 1.02 (95% CI 0.76-1.37) for >3 years of cumulative DA use, respectively.

Conclusions: At typical doses for the clinical management of RLS, long-term DA use was not associated with risk of lung cancer.

References

Bajaj A, Driver J, Schernhammer E . Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010; 21(5):697-707. DOI: 10.1007/s10552-009-9497-6. View

Molnar M, Lu J, Kalantar-Zadeh K, Kovesdy C . Association of incident restless legs syndrome with outcomes in a large cohort of US veterans. J Sleep Res. 2015; 25(1):47-56. PMC: 4795990. DOI: 10.1111/jsr.12335. View

Ung M, MacKenzie T, Onega T, Amos C, Cheng C . Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung Cancer. 2018; 126:89-96. PMC: 6296763. DOI: 10.1016/j.lungcan.2018.10.022. View

Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R . Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018; 7(10):4932-4942. PMC: 6198232. DOI: 10.1002/cam4.1749. View

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

Dela Cruz C, Tanoue L, Matthay R . Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4):605-44. PMC: 3864624. DOI: 10.1016/j.ccm.2011.09.001. View

Freedman D, Wu J, Chen H, Engels E, Enewold L, Freedman N . Associations between cancer and Parkinson's disease in U.S. elderly adults. Int J Epidemiol. 2016; 45(3):741-51. PMC: 5841885. DOI: 10.1093/ije/dyw016. View

Collo G, Cavalleri L, Bono F, Mora C, Fedele S, Invernizzi R . Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018:4196961. PMC: 5817382. DOI: 10.1155/2018/4196961. View

Patel T, Chang F . Parkinson's disease guidelines for pharmacists. Can Pharm J (Ott). 2014; 147(3):161-70. PMC: 4025881. DOI: 10.1177/1715163514529740. View

10.

Pottegard A, Friis S, Sturmer T, Hallas J, Bahmanyar S . Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations. Basic Clin Pharmacol Toxicol. 2017; 122(5):451-459. PMC: 7025319. DOI: 10.1111/bcpt.12946. View

11.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

12.

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

13.

Comella C . Treatment of restless legs syndrome. Neurotherapeutics. 2013; 11(1):177-87. PMC: 3899490. DOI: 10.1007/s13311-013-0247-9. View

14.

Yamamoto H, Yatabe Y, Toyooka S . Inherited lung cancer syndromes targeting never smokers. Transl Lung Cancer Res. 2018; 7(4):498-504. PMC: 6131180. DOI: 10.21037/tlcr.2018.06.01. View

15.

Turner R, Chen Y, Fernandes A . Validation of a Case-Finding Algorithm for Identifying Patients with Non-small Cell Lung Cancer (NSCLC) in Administrative Claims Databases. Front Pharmacol. 2017; 8:883. PMC: 5714924. DOI: 10.3389/fphar.2017.00883. View

16.

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

17.

Weissenrieder J, Neighbors J, Mailman R, Hohl R . Cancer and the Dopamine D Receptor: A Pharmacological Perspective. J Pharmacol Exp Ther. 2019; 370(1):111-126. PMC: 6558950. DOI: 10.1124/jpet.119.256818. View

18.

Wall R, Shyr Y, Smalley W . Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. J Thorac Oncol. 2007; 2(2):109-14. DOI: 10.1097/jto.0b013e31802f1cc5. View

19.

Torre L, Siegel R, Jemal A . Lung Cancer Statistics. Adv Exp Med Biol. 2015; 893:1-19. DOI: 10.1007/978-3-319-24223-1_1. View

20.

Alberg A, Nonemaker J . Who is at high risk for lung cancer? Population-level and individual-level perspectives. Semin Respir Crit Care Med. 2008; 29(3):223-32. PMC: 3399915. DOI: 10.1055/s-2008-1076742. View